Evidence map›Paper›PMID 39643731›Full record

ArticleHuman cell2024

Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.

Yun Gao, Xiaoyun Chen, Yuerong Zhu, Suiqing Zhou, Long Zhang, Qiuyue Wu, Hui Zhang, Ziyi Wang, Xuejiao Chen, Xinyi Xia and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yun GaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Xiaoyun ChenGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Yuerong ZhuDepartment of Clinical Laboratory, Affiliated Hospital of Medical School, Jinling Hospital, Nanjing University, Nanjing, China.
Suiqing ZhouHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Long ZhangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Qiuyue WuInstitute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, the First School of Clinical Medicine, Southern Medical University, Nanjing, 210002, China.
Hui ZhangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Ziyi WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Xuejiao ChenDepartment of General Surgery, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng, China.
Xinyi XiaInstitute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, the First School of Clinical Medicine, Southern Medical University, Nanjing, 210002, China. xinyixia@nju.edu.cn.
Liyong PuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. puliyong@njmu.edu.cn.
Xuehao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. wangxh@njmu.edu.cn.ORCID http://orcid.org/0000-0001-5849-0098

Funding

the Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences 2019PT320015Young Medical Key Talents Foundation of Jiangsu Province ZDRCA2016097
6 · The paper itself

Abstract

Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a unique subtype of primary liver cancer displaying both hepatocytic and cholangiocytic differentiation. The development of effective treatments for cHCC-CCA remains challenging because of its high heterogeneity and lack of a suitable model system. Using a three-dimensional culture system, we successfully established two novel cHCC-CCA organoid lines from patients undergoing surgical resection for primary liver cancer. cHCC-CCA organoid lines were authenticated by fingerprint analysis, and their morphology, growth kinetics, and anchorage-independent growth were also characterized. Hematoxylin and eosin staining and immunohistochemical analysis showed that the cHCC-CCA organoids preserved the growth pattern, differentiation grade, and phenotypic characteristics of their parental tumors. Whole-exome sequencing demonstrated that patient-derived cHCC-CCA organoid lines retained the genetic alterations identified in their original tumors. Subcutaneous tumors developed in immunodeficient mice after injection of cHCC-CCA organoids. Histologically, the xenografts recapitulated the features of the original cHCC-CCA tumors, harboring both HCC and intrahepatic cholangiocarcinoma components within the same tumor. The establishment of patient-derived cHCC-CCA organoid lines with high tumorigenicity provides a valuable resource for the mechanistic investigation and drug development of this disease.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsOrganoidsAnimalsCell Culture TechniquesCell Line, TumorHumansMiceCholangiocytic differentiationCombined hepatocellular cholangiocarcinomaHepatocytic differentiationPatient-derived organoidsTumorigenicity

Identifiers

PMID39643731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.